Flamingo Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Out of Business

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Out of Business

Flamingo Therapeutics General Information

Description

Provider of RNA-targeted therapies intended to target undruggable transcription factors and splice variants for specific cancer types. The company's discovery engine helps mine the dark matter of the genome, exploit lncRNA biology, identify targets that are exquisitely sensitive to antisense modulation, and apply proven antisense chemistry to create targeted cancer therapies, enabling healthcare providers to treat cancers.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Gaston Geenslaan 3
  • 3001 Leuven
  • Belgium
+32 016
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Gaston Geenslaan 3
  • 3001 Leuven
  • Belgium
+32 016

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Flamingo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 05-Apr-2026 Completed Out of Business
2. Early Stage VC 01-Sep-2021 Completed Clinical Trials - Phase 2
1. Early Stage VC 16-Mar-2020 $3.31M $3.31M Completed Clinical Trials - Phase 2
To view Flamingo Therapeutics’s complete valuation and funding history, request access »

Flamingo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A1 Preferred Shares
To view Flamingo Therapeutics’s complete cap table history, request access »

Flamingo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Flamingo Therapeutics Acquisitions (1)

Flamingo Therapeutics’s most recent deal was a Merger/Acquisition with Dynacure. The deal was made on 02-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dynacure 02-Mar-2023 Merger/Acquisition Drug Discovery
To view Flamingo Therapeutics’s complete acquisitions history, request access »

Flamingo Therapeutics FAQs

  • When was Flamingo Therapeutics founded?

    Flamingo Therapeutics was founded in 2020.

  • Where is Flamingo Therapeutics headquartered?

    Flamingo Therapeutics is headquartered in Leuven, Belgium.

  • What is the size of Flamingo Therapeutics?

    Flamingo Therapeutics has 20 total employees.

  • What industry is Flamingo Therapeutics in?

    Flamingo Therapeutics’s primary industry is Drug Discovery.

  • Is Flamingo Therapeutics a private or public company?

    Flamingo Therapeutics is a Private company.

  • What is Flamingo Therapeutics’s current revenue?

    The current revenue for Flamingo Therapeutics is .

  • How much funding has Flamingo Therapeutics raised over time?

    Flamingo Therapeutics has raised $5.25M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process